Skip to main content

iparomlimab/tuvonralimab

Generic: Iparomlimab/Tuvonralimab

iparomlimab/tuvonralimab: 2 clinical trials tracked.

iparomlimab/tuvonralimab evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about iparomlimab/tuvonralimab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Lung Adenocarcinoma

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

Phase 2 Randomized Controlled Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

NCT07413601Registry updated 2026-02-17·Phase 2
Not yet recruiting

Primary endpoint: Median Progression-Free Survival (PFS)

InterventionalRandomizedopen78 targetStarted 2026-02Completion 2029-021 site · ChinaCancer Institute and Hospital, Chinese Academy of Medical Sciences

A Multicenter Study of Iparomlimab and Tuvonralimab (QL1706) Plus Platinum-Based Doublet Chemotherapy and Bevacizumab in PD-L1 ≥50% Non-Squamous Non-Small Cell Lung Cancer With Actionable Genomic Alterations (AGA) Resistant to Prior Targeted Therapy

NCT07416058Registry updated 2026-02-17·Phase 2
Not yet recruiting

Primary endpoint: Objective Response Rate (ORR) per RECIST 1.1

Interventionalopen61 targetStarted 2026-01Completion 2028-12Guangdong Association of Clinical Trials